Novo Nordisk shares fall after raising full-year GLP-1 guidance
Investors sold the stock despite the higher outlook, a sign of how closely the market is watching incretin competition.
The wire
- 01Novo Nordisk raised its full-year guidance on GLP-1 sales, but its shares declined following the update.
- 02Novo's trajectory affects supply, pricing and contracting for semaglutide products that clinics and pharmacies depend on.
- 03The report does not detail the drivers behind the share move; further colour would come from the company's fuller results commentary.
From the source
Read at cnbc.comNovo Nordisk shares fall despite raising full-year guidance on GLP-1 sales